# Sparganii **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/sparganii **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-29 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** Sparganium rhizome lignan, Sparganii Rhizoma extract, Sparganium stoloniferum lignan, San Leng lignan, Bur-reed rhizome compound, Sparganium lignan, Chinese bur-reed extract ## Overview Sparganii (Sparganium stoloniferum) contains bioactive lignans and phenylpropanoids that exert anticancer effects primarily by activating intrinsic apoptotic pathways via caspase-3 and caspase-9. Preclinical research highlights its potential to overcome gefitinib resistance in lung adenocarcinoma and suppress tumor cell migration. ## Health Benefits • Inhibits proliferation of gefitinib-resistant lung adenocarcinoma cells, evidenced by in vitro studies. • Promotes apoptosis in cancer cells via caspase-3/9 activation, as shown in preclinical research. • Reduces migration of cancer cells, supporting potential anti-metastatic effects in vitro. • Downregulates p-AKT1 and p-mTOR, pathways involved in prostate cancer, according to cell studies. • Enhances [mitochondrial](/ingredients/condition/energy)-mediated apoptosis in resistant cancer cell lines, demonstrated in network pharmacology studies. ## Mechanism of Action Sparganii's bioactive lignans and phenylpropanoids trigger the intrinsic [mitochondrial](/ingredients/condition/energy) apoptosis pathway by upregulating pro-apoptotic proteins such as Bax and downregulating Bcl-2, ultimately activating caspase-9 and downstream executioner caspase-3. These compounds also appear to suppress EGFR-related downstream signaling, offering a mechanism to overcome acquired gefitinib resistance in NSCLC cells. Additionally, inhibition of matrix metalloproteinases (MMPs) and interference with epithelial-to-mesenchymal transition (EMT) markers may underlie the observed reduction in cancer cell migration. ## Clinical Summary Current evidence for Sparganii is derived almost entirely from in vitro cell-line studies, including experiments on gefitinib-resistant lung adenocarcinoma (PC-9/GR cells), with no peer-reviewed randomized controlled trials in humans published to date. In vitro models have demonstrated measurable reductions in cell viability and migration at defined extract concentrations, and apoptosis rates were quantified via flow cytometry and caspase activity assays. Animal (rodent) xenograft models have provided preliminary support for tumor growth suppression, but sample sizes are small and study designs vary considerably. The overall evidence strength is low; human pharmacokinetic, safety, and efficacy data are lacking, and clinical translation remains speculative. ## Nutritional Profile Sparganii (Sparganium stoloniferum, San Leng rhizome) is a medicinal herb used in Traditional Chinese Medicine, not typically consumed as a food source, so conventional macronutrient profiling is limited. Known compositional data includes: Bioactive compounds: Phenylpropanoids including ferulic acid (reported at approximately 0.1–0.5 mg/g dry weight), p-coumaric acid, and caffeic acid derivatives. Flavonoids: naringenin and kaempferol glycosides present in trace amounts (<0.1 mg/g). Terpenoids: sesquiterpene lactones and diterpenoids identified as key bioactive constituents, though precise concentrations vary by extraction method. Sterols: beta-sitosterol and stigmasterol detected in lipid fractions. Polysaccharides: crude polysaccharide content estimated at 5–15% of dry weight, contributing to [immunomodulatory](/ingredients/condition/immune-support) effects. Organic acids: succinic acid and oxalic acid present in small quantities. Minerals: moderate potassium content reported; trace amounts of calcium, magnesium, and iron consistent with rhizome-class botanicals, though specific mg/g values lack standardized published data. Crude fiber: estimated 10–20% of dry weight as insoluble fiber from rhizome cell wall material. Protein: approximately 3–8% of dry weight, low biological value. Bioavailability note: Active phenylpropanoids show improved bioavailability with alcohol-based extraction versus aqueous; polysaccharide fractions are poorly absorbed systemically but may exert local gut effects. ## Dosage & Preparation There are no clinically studied dosage ranges for Sparganii Rhizoma in humans. In vitro studies utilized freeze-dried powder at concentrations of 1-8 mg/mL for 24-72 hours. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions No formal human safety or toxicology trials for isolated Sparganii lignans have been published, making it impossible to define a safe or effective clinical dose at this time. Traditional Chinese medicine preparations containing Sparganium stoloniferum are contraindicated in pregnancy due to reported emmenagogue and uterotonic activity, which poses a risk of miscarriage. Potential interactions with anticoagulant drugs (e.g., warfarin) are theoretically plausible given traditional uses involving blood-moving properties, and concurrent use should be avoided until interaction data exist. Individuals with bleeding disorders, those scheduled for surgery, or patients on EGFR-targeted therapies should consult a healthcare provider before use. ## Scientific Research There are no human clinical trials or meta-analyses available for Sparganii Rhizoma. The current evidence is limited to preclinical studies, including network pharmacology and in vitro experiments. ## Historical & Cultural Context Traditionally, Sparganii Rhizoma is used in Chinese medicine for gynecological issues such as dysmenorrhea and abdominal masses. It is combined with Curcumae Rhizoma for treating tumors and blood stasis, with its use documented in classical TCM texts. ## Synergistic Combinations Curcumae Rhizoma, formononetin, beta-sitosterol, bisdemethoxycurcumin, stigmasterol ## Frequently Asked Questions ### What is Sparganii and what plant does it come from? Sparganii refers to the dried rhizome of Sparganium stoloniferum (Bur-reed), a water plant used in Traditional Chinese Medicine. Its primary bioactive constituents are lignans, phenylpropanoids, and flavonoids, which are credited with its observed anticancer and anti-inflammatory activities in preclinical studies. ### Can Sparganii help with drug-resistant lung cancer? In vitro studies using PC-9/GR cells (a gefitinib-resistant lung adenocarcinoma line) showed that Sparganii extracts inhibited cell proliferation and promoted caspase-3/9-mediated apoptosis, suggesting a potential role in overcoming acquired EGFR-inhibitor resistance. However, these findings are limited to laboratory models and have not been confirmed in human clinical trials, so no clinical conclusions can yet be drawn. ### How does Sparganii cause cancer cell death? Sparganii lignans activate the intrinsic apoptotic pathway by shifting the Bcl-2/Bax ratio in favor of Bax, leading to cytochrome c release from mitochondria and sequential activation of caspase-9 and caspase-3. This cascade results in DNA fragmentation and programmed cell death in cancer cell lines tested in vitro. ### Is Sparganii safe to take during pregnancy? Sparganii is traditionally contraindicated during pregnancy in Chinese medicine practice because it is classified as a 'blood-moving' herb with reported emmenagogue and uterotonic properties that could stimulate uterine contractions and increase miscarriage risk. No modern clinical safety data exist to quantify this risk, so pregnant individuals should strictly avoid it. ### What is the recommended dosage of Sparganii supplement? No evidence-based human dosage has been established for isolated Sparganii lignans, as no clinical pharmacokinetic or dose-finding trials in humans have been completed. Traditional Chinese herbal formulations historically use 3–10 g of dried rhizome in decoctions, but these doses apply to whole-herb preparations and cannot be directly extrapolated to standardized lignan extracts or capsule supplements. ### Does Sparganii interact with gefitinib or other cancer medications? While Sparganii demonstrates activity against gefitinib-resistant lung cancer cells in laboratory studies, there is currently limited clinical data on direct interactions with gefitinib or other chemotherapy agents. Individuals taking cancer medications should consult their oncologist before adding Sparganii supplements, as preclinical research has not yet established safe concurrent use protocols. The potential for additive effects on apoptosis pathways warrants medical supervision in therapeutic settings. ### What does current research evidence show about Sparganii's anti-cancer effectiveness? Current evidence for Sparganii is limited to in vitro (cell culture) and preclinical studies demonstrating inhibition of gefitinib-resistant lung adenocarcinoma proliferation and activation of apoptosis through caspase-3/9 pathways. No clinical trials in human subjects have been completed to date, meaning efficacy and safety in living patients remain unproven. These laboratory findings are promising but cannot yet translate to clinical recommendations for cancer treatment. ### Who would benefit most from Sparganii supplementation based on current research? Based on available preclinical data, potential candidates would include individuals interested in supporting cellular health pathways related to p-AKT1 and p-mTOR downregulation, though robust human evidence is absent. Research suggests possible relevance to prostate and lung health, but this remains speculative without human clinical trials. Anyone considering Sparganii for disease management should first discuss its investigational status with their healthcare provider. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*